Ozempic Shows Benefit in Type 1 Diabetes Patients With Obesity

(Medage today) – Chicago – The semaglutide (ozempic) has reduced glucose levels and weight in patients with type 1 diabetes and obesity, has shown a randomized trial. In this double blind trial of 26 weeks of 72 adults, 36% who received 1 mg of …